BB Biotech AG : Update portefeuille : OC relevé à 64 €, Neutre maintenu
>Un T2 2019 marqué par des craintes aux USA et un effet changes négatif - BB Biotech a publié vendredi ses résultats au titre du T2 2019, le titre de la holding a reculé sur le trimestre de 4.8% en € et en CHF sous-performant légèrement son indice de référence le NBI (Nasdaq Biotechnology Index) qui lui a reculé de 4% en € sur la période. La NAV du portefeuille a reculé de 9.4% en CHF, de 8.8% en € et de 7.6% en $. Il en résulte une perte nette de 336 MCHF (vs 98 MCHF...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.